Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day

• Published in: Gan to kagaku ryoho Vol. 40; no. 6; p. 803
• Main Authors: Hanada, Norihisa, Kawata, Kousei, Okamura, Shigeki, Tomiyama, Nariaki, Hori, Kazuki
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.06.2013
• Subjects: Abdominal Neoplasms - pathology; Abdominal Wall - pathology; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Benzamides - administration & dosage; Benzamides - therapeutic use; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - pathology; Humans; Ileal Neoplasms - drug therapy; Ileal Neoplasms - pathology; Imatinib Mesylate; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Middle Aged; Piperazines - administration & dosage; Piperazines - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Recurrence; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Tomography, X-Ray Computed
• ISSN: 0385-0684

Case 1: Recurrent tumors from gastric GIST in the liver and the abdominal wall showed partial response with 200mg/day imatinib and maintained partial response at 100mg/day. Case 2: Metastatic liver tumors from the jejunal GIST showed partial response with 200mg/day imatinib. The tumors have been enlarged for interruption of imatinib administration, however, re- treatment with imatinib resulted in partial response again and kept partial response at 100mg/day of imatinib. The two cases seldom encountered adverse events at 100mg/day of imatinib. There are some cases successfully treated with low-dose imatinib mesylate for recurrent GIST.